• Earlier this month, Moderna announced that the FDA will convene a public advisory committee on June 18, 2026, to review its mRNA-based seasonal flu vaccine for adults aged 50 and older after an initial refusal-to-file setback.
• This review represents a pivotal regulatory test of Moderna’s efforts to build revenue beyond COVID-19 vaccines and prove the broader value of its mRNA platform.
• We’ll now examine how the upcoming FDA advisory panel decision on Moderna’s mRNA flu vaccine could reshape its long-term investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Moderna Investment Narrative Recap

To own Moderna today, you need to believe its mRNA platform can translate into a broader, sustainable portfolio beyond a shrinking COVID-19 franchise, despite ongoing losses. The upcoming FDA advisory panel on its mRNA flu vaccine is still the key near term catalyst and regulatory risk. The recent by-law change around Securities Act litigation does not materially alter that core story, but it underlines how legal and regulatory complexity remains part of the investment case.

The most relevant recent announcement here is Moderna’s May by-law amendment that channels Securities Act lawsuits into U.S. federal courts. Coming just months after a US$2.25 billion LNP patent settlement, it sits alongside the flu advisory committee as a reminder that legal structure, trial design scrutiny, and regulatory feedback could all influence how cleanly Moderna can convert its mRNA pipeline into durable revenue streams.

Yet beneath the promise of a new flu vaccine, investors should be aware that growing regulatory and legal pressures around mRNA products could...

Moderna's narrative projects $3.2 billion revenue and $407.1 million earnings by 2029.

Uncover how Moderna's forecasts yield a $46.10 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a much more pessimistic view, assuming only about 6 percent annual revenue growth and earnings of roughly US$341.4 million by 2029, so if you are weighing the flu review and legal shifts, it is worth comparing these cautious assumptions with your own expectations and exploring how views could change as new data arrives.

Explore 6 other fair value estimates on Moderna - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.